SCHOTT Pharma Extends CEO Contract and Appoints New CFO

SCHOTT Pharma's Supervisory Board has announced the extension of CEO Andreas Reisse’s contract until April 2026. Reisse, who has been with SCHOTT since 1987, spearheaded the "Pharmaceutical Systems" division. His leadership has been pivotal in positioning SCHOTT Pharma as a leader in pharmaceutical containment solutions.

Additionally, CFO Dr. Almuth Steinkühler will step down to explore new career opportunities. She played a critical role in the company’s successful IPO. Reinhard Mayer will replace her as CFO on August 1, 2025. Mayer brings extensive experience in corporate finance and a history of steering multinational companies toward growth.

These leadership changes aim to sustain SCHOTT Pharma's momentum in innovation and global expansion. Both Reisse and Mayer are set to enhance the company's market position and future prospects.